KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Payables (2018 - 2025)

Historic Payables for ClearPoint Neuro (CLPT) over the last 13 years, with Q3 2025 value amounting to $723000.0.

  • ClearPoint Neuro's Payables fell 2429.32% to $723000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $723000.0, marking a year-over-year decrease of 2429.32%. This contributed to the annual value of $1.3 million for FY2024, which is 24096.69% up from last year.
  • As of Q3 2025, ClearPoint Neuro's Payables stood at $723000.0, which was down 2429.32% from $1.5 million recorded in Q2 2025.
  • Over the past 5 years, ClearPoint Neuro's Payables peaked at $10.8 million during Q1 2024, and registered a low of $272000.0 during Q4 2022.
  • Moreover, its 5-year median value for Payables was $1.2 million (2021), whereas its average is $2.1 million.
  • Per our database at Business Quant, ClearPoint Neuro's Payables skyrocketed by 74846.82% in 2024 and then crashed by 8874.91% in 2025.
  • Over the past 5 years, ClearPoint Neuro's Payables (Quarter) stood at $427000.0 in 2021, then plummeted by 36.3% to $272000.0 in 2022, then soared by 44.49% to $393000.0 in 2023, then soared by 240.97% to $1.3 million in 2024, then plummeted by 46.04% to $723000.0 in 2025.
  • Its Payables stands at $723000.0 for Q3 2025, versus $1.5 million for Q2 2025 and $1.2 million for Q1 2025.